Compare Piramal Healthcare with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PIRAMAL ENTERPRISES vs ASTRAZENECA PHARMA - Comparison Results

PIRAMAL ENTERPRISES     Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PIRAMAL ENTERPRISES ASTRAZENECA PHARMA PIRAMAL ENTERPRISES/
ASTRAZENECA PHARMA
 
P/E (TTM) x 14.6 82.6 17.7% View Chart
P/BV x 0.9 23.3 4.0% View Chart
Dividend Yield % 1.9 0.0 -  

Financials

 PIRAMAL ENTERPRISES   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    PIRAMAL ENTERPRISES
Mar-19
ASTRAZENECA PHARMA
Mar-18
PIRAMAL ENTERPRISES/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs3,3031,278 258.4%   
Low Rs1,797883 203.6%   
Sales per share (Unadj.) Rs716.5228.4 313.7%  
Earnings per share (Unadj.) Rs79.710.4 769.0%  
Cash flow per share (Unadj.) Rs107.916.3 663.6%  
Dividends per share (Unadj.) Rs28.000-  
Dividend yield (eoy) %1.10-  
Book value per share (Unadj.) Rs1,477.598.8 1,495.9%  
Shares outstanding (eoy) m184.4525.00 737.8%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x3.64.7 75.2%   
Avg P/E ratio x32.0104.2 30.7%  
P/CF ratio (eoy) x23.666.4 35.6%  
Price / Book Value ratio x1.710.9 15.8%  
Dividend payout %35.10-   
Avg Mkt Cap Rs m470,29227,008 1,741.3%   
No. of employees `0007.81.4 576.7%   
Total wages/salary Rs m22,5041,535 1,465.7%   
Avg. sales/employee Rs Th16,899.44,210.9 401.3%   
Avg. wages/employee Rs Th2,877.71,132.2 254.2%   
Avg. net profit/employee Rs Th1,879.9191.1 983.9%   
INCOME DATA
Net Sales Rs m132,1535,710 2,314.4%  
Other income Rs m3,128123 2,553.5%   
Total revenues Rs m135,2815,833 2,319.4%   
Gross profit Rs m66,290463 14,320.5%  
Depreciation Rs m5,202147 3,528.8%   
Interest Rs m44,0970-   
Profit before tax Rs m20,119438 4,593.3%   
Minority Interest Rs m3,1940-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,611179 4,813.5%   
Profit after tax Rs m14,701259 5,673.9%  
Gross profit margin %50.28.1 618.8%  
Effective tax rate %42.840.8 104.8%   
Net profit margin %11.14.5 245.2%  
BALANCE SHEET DATA
Current assets Rs m122,7423,209 3,824.7%   
Current liabilities Rs m310,8102,070 15,018.6%   
Net working cap to sales %-142.320.0 -713.0%  
Current ratio x0.41.6 25.5%  
Inventory Days Days2372 31.9%  
Debtors Days Days3935 111.2%  
Net fixed assets Rs m116,904790 14,792.4%   
Share capital Rs m36950 737.8%   
"Free" reserves Rs m272,1612,419 11,249.6%   
Net worth Rs m272,5302,469 11,036.7%   
Long term debt Rs m270,1960-   
Total assets Rs m856,2614,605 18,592.5%  
Interest coverage x1.5NM-  
Debt to equity ratio x1.00-  
Sales to assets ratio x0.21.2 12.4%   
Return on assets %6.95.6 122.1%  
Return on equity %5.410.5 51.4%  
Return on capital %12.417.7 70.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,200300 5,074.4%   
Fx outflow Rs m4,8892,015 242.6%   
Net fx Rs m10,312-1,715 -601.1%   
CASH FLOW
From Operations Rs m-115,97588 -131,939.2%  
From Investments Rs m-8,265-94 8,830.2%  
From Financial Activity Rs m107,525NA-  
Net Cashflow Rs m-16,650-6 292,108.8%  

Share Holding

Indian Promoters % 52.9 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 4.0 0.3 1,333.3%  
FIIs % 26.6 15.7 169.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 16.5 9.1 181.3%  
Shareholders   93,274 12,856 725.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PIRAMAL ENTERPRISES With:   DR. REDDYS LAB  IPCA LABS  NATCO PHARMA  AUROBINDO PHARMA  STERLING BIOTECH  

Compare PIRAMAL ENTERPRISES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends above 39,000-Mark; Automobile and Banking Stocks Witness Buying(Closing)

Extending gains to the fifth day, Indian share markets rose sharply during the afternoon session and ended on a strong note.

Related Views on News

ALEMBIC PHARMA Surges by 5%; BSE HEALTHCARE Index Up 0.9% (Market Updates)

Oct 17, 2019 | Updated on Oct 17, 2019

ALEMBIC PHARMA share price has surged by 5% and its current market price is Rs 550. The BSE HEALTHCARE is up by 0.9%. The top gainers in the BSE HEALTHCARE Index are ALEMBIC PHARMA (up 5.2%) and PIRAMAL ENTERPRISES (up 7.0%). The top losers are SYNGENE INTERNATIONAL (down 0.1%) and SHILPA MEDICARE (down 0.3%).

PIRAMAL ENTERPRISES Surges by 5%; BSE HEALTHCARE Index Up 0.2% (Market Updates)

Oct 17, 2019 | Updated on Oct 17, 2019

PIRAMAL ENTERPRISES share price has surged by 5% and its current market price is Rs 1,448. The BSE HEALTHCARE is up by 0.2%. The top gainers in the BSE HEALTHCARE Index is PIRAMAL ENTERPRISES (up 5.1%). The top losers are FORTIS HEALTHCARE and THYROCARE TECHNOLOGIES (down 0.1%).

ASTRAZENECA PHARMA Surges by 6%; BSE HEALTHCARE Index Up 0.1% (Market Updates)

Oct 17, 2019 | Updated on Oct 17, 2019

ASTRAZENECA PHARMA share price has surged by 6% and its current market price is Rs 2,331. The BSE HEALTHCARE is up by 0.1%. The top gainers in the BSE HEALTHCARE Index is ASTRAZENECA PHARMA (up 5.6%). The top losers are THYROCARE TECHNOLOGIES (down 0.1%) and LAURUS LABS LTD (down 0.2%).

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

PIRAMAL ENTERPRISES Announces Quarterly Results (1QFY20); Net Profit Up 390.0% (Quarterly Result Update)

Aug 1, 2019 | Updated on Aug 1, 2019

For the quarter ended June 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 4 bn (up 390.0% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PIRAMAL ENTERPRISES SHARE PRICE


Oct 17, 2019 (Close)

TRACK PIRAMAL ENTERPRISES

  • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PIRAMAL ENTERPRISES

PIRAMAL ENTERPRISES 8-QTR ANALYSIS

COMPARE PIRAMAL ENTERPRISES WITH

MARKET STATS